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Background: Post treatment minimal residual disease (MRD) determination contributes to impending relapse
prediction, chemotherapy response and clinical outcomes assessment, guiding clinicians to develop reasonable and
effective individual chemotherapy options after induction/consolidation. This study was to identify serum candidate
peptides for monitoring adult acute myeloid leukemia (AML) MRD.
Results: 47 statistically different expressed peptide peaks were obtained in the molecular weight range of
700-10000 Da. Quick classifier (QC) model had optimal distinction efficiency, in the training set with a sensitivity of
90% and a specificity of 93.33%. Peptides were identified as ubiquitin-like modifier activating enzyme 1(UBA1),
isoform 1 of fibrinogen alpha chain precursor and platelet factor 4(PF4). The peptide up-regulated in newly
diagnosed AML patients were decreased to the normal level after CR. When refractory & relapsed, relative intensity
was elevated again. Results were contrary to down-regulated peptide peaks. Western blot demonstrated that levels
of the UBA1 protein did not differ between the leukemia and normal cells. Levels of isoform 1 of fibrinogen alpha
chain precursor protein and PF4 protein were both decreased in leukemia cells comparing with normal cells. The
serum levels of the PF4 in the newly diagnosed AML patients and healthy controls were significantly different.
Further correlation analysis did not indicate the correlated relation between platelet counts and PF4 content, the
correlation coefficient was 0.097. Kaplan–Meier analyses of overall survival showed that relative intensity of peptides
was correlated with patient’s clinical outcome.
Conclusions: We speculate the peptides can be used as potential markers for monitoring minimal residual disease
and clinical outcome assessment.
Keywords: Weak cation exchange magnetic beads, MALDI-TOF-MS, Serum peptidome profiling, Adult acute
myeloid leukemia, Minimal residual diseaseBackground
Acute myeloid leukemia(AML), a clonal expansion, ac-
cumulation and infiltration of myeloid hematopoietic
blasts, is a highly heterogeneous hematological ma-
lignancy comprising many entities for which distinct
treatment strategies are pursued [1]. Although M3 is a
success story in AML oncology (cure rate more than
90%), clinical effects in non-M3 AMLs lag behind those
in M3 [2]. The poor long-term disease-free survival rates* Correspondence: heaili@mail.xjtu.edu.cn; zhangwanggang2003@yahoo.com
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reproduction in any medium, provided the orof adult AML is mainly due to therapy-related mortality,
failure of induction chemotherapy and early relapse [3].
Risk stratification adapted therapies based on prognostic
factors will help to improve the clinical outcomes. But
indeed, patients with favorable karyotype accounts for
approximately 40% to 50% of low-risk AML will even-
tually experience a relapse. For patients falling into the
intermediate risk karyotype (~60%), post remission stra-
tegies-planning lacks accepted criteria. Lots of studies
have shown that minimal residual disease (MRD) posi-
tive patients are at high risk of relapse, while MRD-
negative cases manifest lower risk of relapse in patients
with acute promyelocytic leukemia and acute lym-
phoblastic leukemia clinically. Nowadays, post treatmentThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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trapolating the risk of relapse, assessing chemotherapy
response and planning individual chemotherapy regimen
after induction/consolidation [4].
Leukemia relapse is mainly due to the presence of
MRD. Leukemia MRD level monitoring contributes to
anticipation of impending relapse and assessment of
clinical outcomes, guiding clinicians to develop reason-
able and effective treatment options so that patients can
avoid unnecessary chemical drug toxicity. Currently,
MRD monitoring is mainly through detecting remaining
leukemia cells in bone marrow by multi-parameter flow
cytometry phenotype analysis and real-time quantita-
tive polymerase chain reaction (RTQ-PCR). But multi-
parameter flow cytometry phenotype analysis can’t be
carried out in lots of hospitals and lack standardized
procedure, the number of fusion genes known in acute
leukemia is limited and RTQ-PCR assays shows poverty
in standardized cut-offs. Moreover, bone marrow aspir-
ation is invasive and increases the patient’s pain. Because
most non-M3-AML patients lack specific fusion genes,
so after every stage of chemotherapy, the response is
mainly judged by whether the leukemia cells in the bone
marrow are less than 5%. As bone marrow aspiration site
is single, leukemia cells are not typical after multiple
chemotherapy, bone marrow smears need long-term
film-reading experience and skilled clinical hemato-
logical workers to read. Serum is easily accessible, can
record different physiological or pathological conditions
at any time and readily accepted by patients, there-
fore, it becomes one of the best sources for biomar-
kers researching.
Serum peptide profile method is known as “The new
health fingerprint library” technology and has been ac-
cepted worldwide. It is through analysing and comparing
differences in the expression of serum peptides between
target population and normal healthy population, to find
multiple different-expressed serum peptides, to map out
disease-specific serum peptide spectrum, to diagnose
disease, to clarify the possible pathogenesis and resis-
tance mechanism, and to determine prognosis [5].
Proteomics technology has been applied to study he-
matological malignancies in some previous researches.
The traditional two-dimensional gel electrophoresis
(2-DE)-based separation technology combined matrix
assisted laser desorption ionization time of flight mass
spectrometry (MALDI-TOF-MS) or Protein chip-surface
enhanced laser desorption ionization time of flight mass
spectrometry (SELDI-TOF-MS) technology were mainly
used to study cell lines and/or bone marrow cells. The
aim of those researches was to find early diagnostic
markers, to predict the prognosis of hematologic malig-
nancies, to explore the molecular mechanisms of anti-
cancer drugs and to develop molecular targeted drugsbased on theses biomarkers. Although the cultured cell
lines have high purity and are easy to operate, but they
are difficult to reflect the real situation of the disease.
Due to the complex composition and high cell hetero-
geneity of bone marrow, researchers analyzed serum
samples of different hematologic malignancies in recent
years using 2-DE combined with MALDI-TOF-MS or
Protein chip-SELDI-TOF-MS, for instance, Albitar [6],
Zou [7] and Mohamedali [8] had established the diag-
nostic model of leukemia with high sensitivity and
specificity, and further identified the leukemia-related
markers, such as Rho-GDP dissociation inhibitor auto-
antibodies, alpha enolase, aldolase enzyme A and so on
[9]. These markers play an important role in the early
diagnosis, differential diagnosis and pathogenesis of acute
leukemia.
In order to facilitate peptide identification, we replaced
solid chip with beads for sample purification and enrich-
ment, and we employed MALDI-TOF MS technology
for mass spectra acquisition, and highly sophisticated
data mining algorithms for inspection and comparison
of data sets as well as for the discovery of complex bio-
marker pattern models [10]. The ClinProt technology
has lots of advantages, such as a large separation capacity
[11], enriched samples easy to elute for further identifica-
tion [12], simple and quick operation, high-throughput,
software parallelization analysis, differentially expressed
forms, etc. [13]. ClinProt technology-based serum peptide
spectra was first used in ovarian cancer research [14],
then widely used for early diagnosis, pathogenesis in-
terpretation, therapeutic targets selection in melanoma
[15], colorectal [16], breast cancer and other solid tumors
[17,18]. Previously, our group applied ClinProt system to
compare and analysis the difference between newly diag-
nosed multiple myeloma (MM) and healthy controls in
serum peptide spectrum, and we established a diagnostic
model with high sensitivity and specificity based on Super-
vised Neural Network Algorithm (SNN) [19].
In view of this, this study used weak cation exchange
magnetic beads (MB-WCX) combined with MALDI-
TOF-MS to analyze serum peptide profiling of adult
AML patients in different disease groups (newly diag-
nosed group, complete remission (CR) group, refractory
& relapsed group) and healthy control group, and then
used high performance liquid chromatography electro
spray ionization tandem mass spectrometry (HPLC-ESI-
MS/MS) to identify candidate peptides. These protein
fragments were validated by immunoblotting. Three pep-
tides are identified as ubiquitin-like modifier activating
enzyme 1(UBA1), isoform 1 of Fibrinogen alpha chain
precursor and platelet factor 4(PF4). They are correlated
with AML clinical outcome and would be appropriately
adapted for predicting AML relapse, monitoring MRD
and predicting prognosis in clinical practice.
Table 1 Reproducibility of mass spectra processed by
ClinProt system
m/z Within-run arrays Between-run arrays
MRI% CV% MRI% CV%
973.15 4.2 14.2 4.1 14.3
1866.09 8.8 9.8 8.6 10.5
2661.27 2.1 8.3 2.2 8.6
3443.92 4.9 12 5.2 12.4
4089.70 3.4 23 3.2 23.4
4208.76 13.1 16.5 13.6 17.2
5902.57 10.1 14.6 10.8 15.3
6628.07 7.2 18.1 6.9 20.9
7762.87 6.1 24.8 5.8 27.3
9288.31 1.7 5.6 1.6 6.4
m/z mass to charge ratio, MRI mass relative intensity, CV coefficient
of variation.
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Repeatability of ClinProt system based peptidome
detection
ClinProt system repeatability was evaluated based on the
serum peptide fingerprints of the same serum sample
processed in triplicate (Additional file 1: Figure S1). The
two figures show that the peptide peaks are consistent in
the three detections, indicating that ClinProt system has
good repeatability.
Moreover, coefficient of variation (CV) value was used
to evaluate repeatability and stability of serum peptide
fingerprint in international. It is required that CV should
be less than 30% [20]. In this study, the CV of the
relative intensity of peptides in MALDI-TOF-MS pep-
tide spectra was calculated to evaluate repeatability ofFigure 1 Serum peptide fingerprint and cluster analysis of newly diag
fingerprints between AML patients and healthy controls showed that peak
(Red: AML newly diagnosed group Green: Healthy control group).the serum peptide fingerprints method (Table 1). The
average CV value of within-run arrays was 14.7%
(5.6%-24.8%) and that of between-run arrays was 15.6%
(6.4%-27.3%).
Analysis of newly diagnosed AML and healthy control
serum peptide fingerprint by ClinProt system
To screen serum peptides of interest for AML, we made
the comparison in serum peptide fingerprints between
AML patients and healthy controls, showing that peak
number and intensity of newly diagnosed AML pa-
tients’ serum peptide fingerprint were completely different
from healthy controls’ (Figure 1), these significant dif-
ferent mass peaks were likely to be the AML potential
characteristic peptides.
Comparative analysis of peptide fingerprint revealed
that there were a total of 47 different expressed peptide
peaks with statistical significance in the MW range of
700–10000 Da (p < 0.05). Among which, the expressions
of 12 peptides were up-regulated and that of 35 peptides
were down-regulated in AML newly diagnosed group
(Table 2).
Establishment QC diagnostic model and blind verification
Genetic algorithm (GA), SNN and QC were applied to
establish diagnostic model for distinguishing newly diag-
nosed AML from healthy control. Among them, QC
model composed of three peptides had optimal distinc-
tion efficiency (90% sensitivity and 93.33% specificity) in
the training set.
In the QC model, the peptide with MW of 3216.57 Da
was up-regulated in AML newly diagnosed group
(Figure 2A), peptides with MW of 4089.7 Da and
7762.87 Da were both down-regulated (Figure 2B,C).nosed AML and healthy control. Comparison of serum peptide
number and intensity of the two groups were completely different.
Table 2 Different expression peptides between newly diagnosed AML group and healthy control group
Index Mass Dave P value Ave1 Ave2 StdDev1 StdDev2 Expression change
48 4208.76 29.66 0.00000192 10.64 40.31 10.37 13.98 ↓
12 1866.09 18.67 0.000489 22.08 3.41 25.9 1.6 ↑
60 5902.57 16.49 0.0000421 10.02 26.51 9.35 11.59 ↓
64 6628.07 9.4 0.00000388 13.85 4.45 7.71 3.24 ↑
69 9286.53 7.84 0.00000192 2.34 10.19 2.03 4.38 ↓
34 3262.18 7.49 0.0000723 5.78 13.27 7.05 6.55 ↓
42 4089.7 7.39 0.00000108 2.69 10.08 1.39 4.03 ↓
66 7762.87 6.42 0.00000108 1.94 8.36 1.25 3.35 ↓
4 1282.99 5.83 0.00000203 2.57 8.41 0.63 6.16 ↓
52 4643.21 5.66 0.0000168 2.37 8.03 1.75 4.4 ↓
5 1299.56 5.53 0.00000108 2.33 7.87 0.57 5.26 ↓
30 2990.42 5.3 0.00000146 6.88 1.57 5.08 0.68 ↑
36 3315.58 5.05 0.00000203 7.05 2 3.74 1.15 ↑
31 3191.17 4.61 0.00000625 2.7 7.31 1.63 3.51 ↓
19 2168.67 4.45 0.0000573 2.04 6.5 0.71 5.51 ↓
39 3950.86 4.17 0.00000203 2.56 6.73 1.27 2.76 ↓
20 2184.85 4.05 0.0116 2.54 6.59 1.06 5.72 ↓
29 2952.24 4.03 0.00616 4.57 8.6 3.14 5.22 ↓
47 4192.99 4.01 0.00000515 2.46 6.48 1.31 2.79 ↓
18 2105.44 3.74 0.0000127 3.05 6.79 1.55 2.99 ↓
56 5335.01 3.21 0.000605 3.42 6.62 2.95 3.29 ↓
40 4052.81 3.07 0.000206 3.13 6.21 2.83 2.37 ↓
62 6430.27 3.02 0.0000335 4.67 1.66 3.69 1.13 ↑
2 1100.81 2.86 0.000259 2.62 5.48 1.01 3.23 ↓
13 1982.13 2.55 0.000137 2.21 4.75 0.63 3.1 ↓
37 3882.23 2.53 0.000257 2.19 4.73 1.01 2.17 ↓
16 2062.28 2.38 0.0000723 1.69 4.07 0.45 2.68 ↓
25 2768.83 2.28 0.00000108 1.81 4.09 0.51 1.52 ↓
15 2037.71 2.26 0.0075 1.84 4.1 0.35 3.12 ↓
17 2069.96 2.19 0.000749 2.02 4.21 0.46 2.65 ↓
59 5864.9 2.18 0.000247 2.47 4.65 1.15 1.85 ↓
53 4818.02 2.17 < 0.000001 2.68 0.51 3.32 0.18 ↑
50 4265.7 1.88 0.000749 2.46 4.34 1.07 1.85 ↓
14 2021.95 1.8 0.00326 4.64 2.84 2.37 3.02 ↑
28 2932 1.59 0.000605 2.63 4.22 0.81 1.56 ↓
46 4167.87 1.56 0.0000437 1.69 3.25 0.84 1.02 ↓
41 4071.18 1.39 0.000029 1.53 2.92 0.38 0.94 ↓
33 3240.42 1.23 0.00958 7.47 8.7 9.41 3.17 ↓
65 6662.81 1.13 0.0000187 2.28 1.15 0.93 0.56 ↑
61 5957.41 1.08 0.0000299 1.06 2.14 0.26 0.95 ↓
32 3216.57 1.04 0.00357 2.87 1.83 1.45 0.53 ↑
63 6526.9 0.79 0.00000268 1.37 0.58 0.52 0.25 ↑
44 4121.48 0.78 0.000259 1.62 2.4 0.38 0.71 ↓
38 3933.89 0.77 0.0000406 1.42 2.19 0.38 0.65 ↓
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Table 2 Different expression peptides between newly diagnosed AML group and healthy control group (Continued)
21 2561.11 0.69 0.0309 2.59 1.9 1.27 0.63 ↑
43 4108.19 0.66 0.000357 1.37 2.03 0.42 0.56 ↓
45 4152.3 0.18 0.0206 2.41 2.22 2.65 0.68 ↑
Index peptide peak index, Mass mass to charge ratio value, Dave differences of average peak intensity between newly diagnosed AML group and healthy
control group, P value p value of t-test, Ave1 average peak intensity of newly diagnosed AML group, Ave2 average peak intensity of healthy control group,
StdDev1 standard deviation of the peak intensity average of newly diagnosed AML group, StdDev2 standard deviation of the peak intensity average of healthy
control group.
Bai et al. Proteome Science 2013, 11:39 Page 5 of 16
http://www.proteomesci.com/content/11/1/39Blind test verified that this model correctly identified 40
cases out of total 42 AML cases and 39 healthy cases
from 42 healthy controls.
Peptide identification
The three peptides in QC model were purified and iden-
tified by HPLC-ESI-MS/MS. Data analysis software
Bioworks Browser 3.3.1 SP1 was performed for Sequest™
searching. Positive protein identification was accepted
for a peptide with Xcorr of greater than or equal to 3.50
for triply charged ions and 2.5 for doubly charged ions,
and all with ΔCn ≥ 0.1, peptide probability ≤ 1e-3. The
three peptides were identified as ubiquitin-like modifier
activating enzyme 1(UBA1), isoform 1 of Fibrinogen
alpha chain precursor and platelet factor 4(PF4), respec-
tively (Table 3). Figures 3, 4 and 5 show the identifica-
tion of specific b and y ions for sequences of the three
peptides.
Determination of serum PF4 by enzyme linked
immunosorbent assay
We detected serum PF4 content by enzyme linked
immunosorbent assay (ELISA) in 40 cases of newly
diagnosed AML and 40 healthy controls. Compared
with healthy control group, PF4 content in newlyFigure 2 Different relative intensities of three peptide peaks between
Upregulated of the peptide with MW of 3216.57 Da in AML newly diagnos
AML newly diagnosed group. (C) Down regulated of the peptide with MW
diagnosed group Green: Healthy control group).diagnosed AML group was decreased (newly diag-
nosed AML vs. control, 0.8012 ± 0.1876 vs. 3.2604 ±
1.0454, p = 1.8638E-6). To eliminate the influence of
platelet count on serum PF4 content, correlation ana-
lysis was further done between platelet count and PF4
content. Correlation coefficient was 0.213 (p = 0.186),
and no correlation was found between them (Figure 6). It
follows that reduction of serum PF4 content in newly di-
agnosed AML is not due to thrombocytopenia.Validation of protein fragment by immunoblotting
Next, we sought to determine the level of UBA1, isoform
1 of fibrinogen alpha chain precursor and PF4 protein in
AML and control samples by western blot analysis.
Levels of the UBA1 protein did not differ among the
leukemia and normal cells by immunoblotting (p = 0.849,
Figure 7A,B). Isoform 1 of fibrinogen alpha chain precur-
sor and PF4 immunoreactive bands show that weak or no
bands are seen in newly diagnosed and refractory & re-
lapsed AML cases (Figure 7A). Quantification of bands
from western blot analysis showed decreased level of the
two proteins in AML samples, relative to age-matched CR
AML and healthy control samples significantly (p =
0.00368, p = 0.00067, Figure 7C,D).AML newly diagnosed group and healthy control group. (A)
ed group. (B) Down regulated of the peptide with MW of 4089.7 Da in
of 7762.87 Da in AML newly diagnosed group. (Red: AML newly
Table 3 Peptides sequencing and identification results
Molecular
weight
Amino acid sequence International
protein index
Peptide name
3216.57 Da HGFESGDFVSFSEVQGMVELNGNQPMEIK IPI00641319 Ubiquitin-like modifier
activating enzyme 1
4089.7 Da GDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV IPI00021885 Isoform 1 of Fibrinogen
alpha chain precursor
7762.87 Da EAEEDGDLQCLCVKTTSQVRPRHITSLEVIKAGPHCPTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES IPI 00022446 Platelet factor 4
Figure 3 MS/MS map of peptide with MW of 3216.57 Da. (A) The enlarged picture of peptide with MW of 3216.57 Da. (B) The b and y ions
spectra used to identify the peptide with MW of 3216.57 Da. (C) The sequence of the peptide with MW of 3216.57 Da.
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Figure 4 MS/MS map of peptide with MW of 4089.7 Da. (A) The enlarged picture of peptide with MW of 4089.7 Da. (B) The b and y ions
spectra used to identify the peptide with MW of 4089.7 Da. (C) The sequence of the peptide with MW of 4089.7 Da.
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AML different groups
To explore the clinical significance of QC model, we
compared the differences in the expression intensity
of the three peptides (3216.57 Da, 4089.7 Da and
7762.87 Da) between AML newly diagnosed group,
CR group, relapsed & refractory group and healthy control
group (Table 4).
The relative intensity of peptide with MW of
3216.57 Da was elevated in the AML newly diagnosed
group and the relapsed & refractory group, but no sig-
nificant difference was observed between the two groups
(p = 0.693). The relative intensity was reduced in the
healthy control group and the CR group, no signifi-
cant difference was observed between the two groups
(p = 0.83) either. But the relative intensity was signifi-
cant elevated in newly diagnosed group and refractory& relapsed group, compared with healthy control
group and CR group (p = 0.00357, p =0.0012, p = 0.0027,
p = 0.0073).
The relative intensities of the peptides with MW of
4089.7 Da and 7762.87 Da were both reduced in the
AML newly diagnosed group and the refractory & re-
lapsed group, but no statistical difference was observed
between the two groups (p = 1.63, p = 0.53). The relative
intensities were elevated in the healthy control group
and the CR group, no significant differences were ob-
served between the two groups (p = 1.92, p = 0.83) ei-
ther, but the relative intensities were significantly
reduced in the newly diagnosed group and the refrac-
tory & relapsed group, compared with healthy control
group and CR group (p = 0.00357, p = 0.0012, p =0.0027,
p = 0.0073, p = 0.00000108, p = 0.00000118, p = 0.00000001,
p = 0.00000021).
Figure 5 MS/MS map of peptide with MW of 7762.87 Da. (A) The enlarged picture of peptide with MW of 7762.87 Da. (B) The b and y ions
spectra used to identify the peptide with MW of 7762.87 Da. (C) The sequence of the peptide with MW of 7762.87 Da.
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survival
The median follow-up duration among 72 patients was
19 months (range 4–38 months). The patients were ca-
tegorized into two groups according to the relative in-
tensity of peptides (≥mean versus <mean). Kaplan–Meier
analyses of overall survival (OS) showed that patients with
higher relative intensity of ubiquitin-like modifier activat-
ing enzyme 1(≥mean relative intensity) had a significantly
inferior outcome. Lower relative intensity of ubiquitin-like
modifier activating enzyme 1(<mean relative intensity)
was associated with an favorable OS (19.9 ± 7.0% versus
42.5 ± 9.8%, P = 0.037; Figure 8A). The OS rate was higher
in patients with increased relative intensity (≥mean re-
lative intensity) of isoform 1 of fibrinogen alpha chain
precursor and platelet factor 4 than in those with
decreased relative intensity (<mean relative intensity)
(48.5 ± 10.7% versus 19.2 ± 7.2%, p = 0.015; 48.5 ± 9.0%
versus 21.7 ±8.5%, P = 0.031, Figure 8B and C).Discussion
AML is a highly heterogeneous disease with distinct
manifestations and prognostic and therapeutic implica-
tions. Leukemia MRD level monitoring contributes to
impending relapse anticipation and clinical outcomes as-
sessment, further guide’s clinicians to develop reasonable
and effective treatment options so that patients can avoid
unnecessary chemical drug toxicity.
Our QC model composed of three peptides achieved
high sensitivity (90%) and specificity (93.33%) between
newly diagnosed AML group and healthy controls. The
peptides may be unique to AML and the AML specimen
volume is up for augmentation for verification. The pep-
tides could be purified to analyze their functions, so as
to clear whether they are implicated in leukemogenesis.
Through document retrieval, there are only two
workers applied ClinProt technology for studying AL pa-
tients serum peptide fingerprint to seek for the AL bio-
markers. Elssner’s group made a comparative analysis of
Figure 6 Correlation analysis between serum PF4 and platelet count in newly diagnosed AML.
Figure 7 Validation of protein fragment by immunoblotting. (A) Levels of the UBA1 protein did not differ among the leukemia and normal
cells. Isoform 1 of fibrinogen alpha chain precursor and PF4 immunoreactive bands show that weak or no bands are seen in newly diagnosed
and refractory & relapsed AML cases. (B) Densitometry comparison of UBA1 protein relative to β-actin as determined by western blot analysis in
figure A. (C) Densitometry comparison of isoform 1 of fibrinogen alpha chain precursor protein relative to β-actin as determined by western
blot analysis in figure A. (D) Densitometry comparison of PF4 protein relative to β-actin as determined by western blot analysis in figure A.
(UBA1: ubiquitin-like modifier activating enzyme 1; FGA: isoform 1 of fibrinogen alpha chain precursor; PF4: platelet factor 4; AML-CR: AML
complete remission; AML-ND: AML newly diagnosed; AML-RR: AML refractory & relapsed).
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Table 4 Relative intensity of three peptides in AML different groups and healthy control group
Mass Ave1 ± StdDev1 Ave2 ± StdDev2 Ave3 ± StdDev3 Ave4 ± StdDev4 n1 n2 n3 n4
3216.57 2.87 ± 1.45 1.83 ± 0.53 1.76 ± 0.48 3.08 ± 1.58 72 72 37 30
4089.7 2.69 ± 1.39 10.08 ± 4.03 11.63 ± 4.51 2.51 ± 1.35
7762.87 1.94 ± 1.25 8.36 ± 3.35 8.62 ± 3.55 1.73 ± 1.18
Mass mass to charge ratio value, Ave average peak intensity, StdDev standard deviation of the peak intensity, n number of patients, 1 AML newly diagnosed
group, 2 healthy control group, 3 AML CR group, 4 AML refractory & relapsed group.
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and healthy controls and obtained an optimum discrimi-
natory pattern proposed by ClinProTools after MB-HIC
C8 enrichment. This model contained four relevant
peaks: 2438 m/z, 6458 m/z, 7771 m/z and 9421 m/z.
They may be four potential biomarkers for childhood
ALL [21]. Liang’s group performed Copper-chelated
magnetic bead fractionation/MALDI-TOF-MS analysis
on sera from patients with newly diagnosed AML, CR
after chemotherapy and healthy control, found that two
peptides with m/z 1778.05 and 1865.13 were gradually
decreased in their relative intensities with increase of re-
mission degree, especially in molecular remission. With
FT-ICR-MS detection, both peptides were identified as
fragments of complement C3f, suggesting that the two
peptides have the potential for monitoring of MRD [22].
The AML candidate peptides screened in our study
are different from those in previous studies. The specific
reasons are as follows: 1) Technically, we applied MB-
WCX based ClinProt system. Some researchers made
a comparison among beads with hydrophobic interac-
tion chromatography C8 (MB-HIC-C8), MB-WCX and
immobilized metal-ion affinity chromatography (MB-
IMAC-Cu), indicating that the serum samples purified
by MB-WCX group provided the best proteomic pat-
tern. These samples had the most average peak numbers,
the highest peak intensities, and the best capturing
ability of low abundance proteins or peptides [23]. Be-
sides low degree of automation, time-consuming and
poor repeatability, traditional 2-DE had an ineffectiveFigure 8 Correlation between relative intensity of three peptides and
of ubiquitin-like modifier activating enzyme 1(≥mean relative intensity) had
patients with increased relative intensity (≥mean relative intensity) of isofo
platelet factor 4(<mean relative intensity) associated with an unfavorable Odetection of proteins with low-abundance, hydrophobi-
city, extreme alkalinity, extreme acidity, very high mo-
lecular weight (>200 kD) or very small molecular weight
(<10 kD). The reproducibility of mass-spectral peaks
abtained by protein chip-SELDI-TOF-MS in different re-
search groups was very low. Target protein bound to the
chip is difficult to elute for further identification. Label-
free quantification strategies using high-resolution mass
spectrometers do not require isotope label as internal
standards and are economic as well as high-throughput.
However, label-free quantitative proteomic techniques is
still not mature enough and has great dependence on
the reproducibility of the MS Experiment. Compared
with isotope-labeling methods, label-free experiments
need to be more carefully controlled due to possible
error caused by run-to-run variations in performance of
LC and MS [24]. The cDNA Microarray is applied to
find disease-related markers from mRNA levels, whereas
protein is the practitioner of human life activities. Pro-
tein with abnormal regulation and modification are al-
ways involved in malignant processes of AML with
normal chromosomes and genes. 2) Serum specimens
were as our study object, excluding the impact of fi-
brinogen and anticoagulant. Unlike some previous re-
port, sera were pre-treated with urea and CHAPS. We
used non-denatured serum samples. 3) We observed the
peptides ranging from 700 to 10000 Da. Peptides as
potential biological information molecules were quite
abundant in serum. Comparing with proteins, peptides
have the advantages of small MW, easy-transformedoverall survival (OS). (A) Patients who had higher relative intensity
a significantly inferior outcome. (B) The OS rate was higher in
rm 1 of fibrinogen alpha chain precursor. (C) Lower relative intensity of
S.
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is a complex process in which lots of peptides are in-
volved. It needs high throughput proteomics technology
to identify theses peptides. The structure of these pep-
tides, their function and role in the pathological process
of disease are expected to be further clarified so as to
better defining disease pathogenesis and guiding clinical
practice.
The relative intensity differences of the peptides in the
QC diagnostic model were further compared in the
AML different groups and the healthy control group.
We found that the peptide with elevated relative inten-
sity in newly diagnosed group was reduced after
complete remission, when relapsed, its relative intensity
again increased; the peptides which were down-
regulated in the newly diagnosed group were upregu-
lated after complete remission and down-regulated when
relapsed. Kaplan–Meier analyses of OS show a signifi-
cantly inferior outcome for patients with higher relative
intensity of ubiquitin-like modifier activating enzyme 1
peptide fragment compared with the patients with
lower relative intensity. The other two peptides with
lower relative intensities were negatively correlated
with patients’ overall survival. All these data suggest
that these peptides can be used as potential predictive
markers of treatment response, disease relapse, moni-
toring minimal residual disease and clinical outcome
assessment.
Ubiquitin-like modifier activating enzyme 1 is also
known as Ubiquitin-activating enzyme E1. Ubiquitin-
proteasome pathway, an important protein quality con-
trol system in eukaryotic cells, is the major route by
which cells rid themselves of excess proteins, such as
damaged or unwanted intracellular proteins to regulate
cell proliferation and differentiation, cell cycle progres-
sion, cell signal transduction, ultimately to maintain the
cell normal function. Ubiquitination is a multistep en-
zymatic cascade in which ubiquitin is conjugated to
target proteins with the assistance of E1 (Ubiquitin-
activating enzyme), E2 (Ubiquitin-conjungating enzyme)
and E3 (Ubiquitin ligase), then recognized, unfolded, and
degraded by the proteasome enzyme complex [25,26].
The ubiquitin pathway has been implicated in several
forms of malignancy through the degradation of tumor
suppressor proteins [26]. In uterine cervical carcinomas,
the tumor-suppressor protein p53 is tagged by the
human papilloma virus (HPV) oncoprotein E6 for
ubiquitin-mediated degradation resulting in transformed
cells [27]. By immunoblotting, Xu’s group found the
levels of ubiquitinated proteins were significantly in-
creased in leukemia cell line K562, U937, NB4, THP1
and leukemia cells from 12 de novo AML patients com-
pared with normal hematopoietic cells. But the levels of
E1 protein in malignant cells did not differ from that innormal cells. Thus, these results suggest that the in-
creased activity of pathway is not due to a greater abun-
dance of the E1 enzyme, while E1 enzyme is more
actively used in malignant cells. Inhibition of E1 enzyme
activity of the four leukemia cell lines by RNA interfer-
ence and chemical inhibitors PYZD-4409 can induce cell
death, and an increase in p53 content, the same result
was seen in multiple myeloma LP1 cell lines and the
My-5 cells. Finally, in a mouse model of leukemia
established by hMDAY-D2, Intraperitoneal administra-
tion of PYZD-4409 decreased tumor weight and volume
compared with control without untoward toxicity [28].
We found that the relative intensity of serum ubiquitin-
like modifier activating enzyme 1 peptide was elevated
in newly diagnosed AML patients compared with
healthy controls. But UBA1 protein levels in leukemia
cells and normal cells are not different by immunoblot-
ting. Maybe some growth negative regulator proteins of
AML have an increased ubiquitination due to increased
E1 enzyme activity but not a greater abundance of the
E1 enzyme. These proteins are further degraded leading
to leukemogenesis. The relative intensity of this peptide
was declined in the AML patients in CR after chemo-
therapy and negatively regulate proteins might have a re-
duced degradation, but its relative intensity was
increased again when AML relapsed, suggesting that the
peptide may play a role in the pathogenesis of AML. It
can be potential indicators for predicting AML treat-
ment response and monitoring MRD. Its function and
biological activity need further studies.
Fibrinogen is a glycoprotein composed of three pairs
of unequal polypeptide chain. Fibrinogen alpha chain is
just one of the three chains present in the circulating fi-
brinogen molecule (the other two being beta and
gamma). A number of studies has shown that there are
an increased expression of fibrinogen in many malignant
tumors, such as pancreatic cancer, renal cell carcinoma,
endometrial carcinoma, osteosarcoma, esophageal squa-
mous cell carcinoma and so on [29]. Preston’s group
considered that fibrinogen as an acute phase protein in
pancreatic cancer had increased expression, because the
result of increased synthesis of fibrinogen was associated
with an ongoing inflammatory response to tumor [30].
Some studies suggest that tumor cells could promote co-
agulation process by interacting with endothelial cells
and platelets, then by releasing active biological sub-
stances that activate platelets, which leads to high level
of fibrinogen in the cancer patients’ blood. It is further
indicated that fibrinogen could be an independent prog-
nostic factor for disease-free, distant-free and overall
survival in endometrial cancer, esophageal cancer and
renal cell carcinoma [31-34]. The relative intensity of
isoform 1 of fibrinogen alpha chain precursor peptide
fragment was decreased in newly diagnosed AML and
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remission. When AML patients relapsed, the relative in-
tensity was reduced again. The results have been validated
by western blot analysis. We found fibrinogen α chain was
highly expressed in newly diagnosed AML serum by
ELISA (Data isn’t shown). It appears that a large part of
the human serum peptidome as detected by MALDI-TOF
MS is produced ex vivo by degradation of endogenous
substrates by endogenous proteases. Peptides are gener-
ated during the proteolytic cascades that occur in the in-
trinsic pathway of coagulation and complement activation.
Some of these are known bioactive molecules, others rep-
resent cleaved propeptides, and still others are seemingly
random internal fragments of the precursor proteins.
However, the observed cleavage sites are generally con-
sistent with trypsin- and chymotrypsin-like activities of
known serine proteases (kallikreins, plasmin, thrombin,
factor I, etc.) [17]. The peptide identified (G592-V629)
could be a putative plasmin- generated proteolytic frag-
ments. In the light of this evidence, a down-regulation of
the identified peptide (4089.7 Da) could be due to a hypo-
thetical reduced enzymatic activity able to attack the C-
terminal end of fibrinogen alpha chain.
PF4 is ELR (−) CXC chemokines, synthesized by me-
gakaryocyte, stored in platelet alpha particles. Shi’s group
used WCX2-Proteinchip arrays and SELDI-TOF-MS,
HPLC-LC-MS/MS found that pediatric ALL patients
had a reduced PF4 expression [35]. Kim’s group found
that PF4 protein levels were a good indicator for the
recovery of blood count in the complete remission of
acute myeloid leukemia [36]. Our study showed that
compared with healthy control group, the relative inten-
sity of PF4 was reduced in newly diagnosed AML group.
The relative intensity was elevated to normal level after
AML patients achieved CR. When AML refractory & re-
lapsed, the relative intensity was decreased again. By im-
munoblotting, PF4 protein was significantly decreased in
newly diagnosed and refractory & relapsed AML cells.
These findings are consistent with Kim’s. As PF4 is se-
creted by platelets and hematologic malignancies always
have reduced platelets. In order to determine whether
the reduced serum PF4 expression was associated with
reduced platelet in MDS patients and benzene-exposed
workers, studies revealed that lower PF4 expression was
not due to thrombocytopenia [37,38]. We determined
and compared serum PF4 content between newly diag-
nosed AML with and without thrombocytopenia. We
found no difference between the two groups. Linear re-
gression analysis showed that no correlation between
PF4 content and platelet count.
Conclusions
In conclusion, AML QC model had high sensitivity and
specificity to discriminate AML patients from healthycontrols by application of ClinProt system with high
throughput and good repeatability. Ubiquitin-like mo-
difier activating enzyme 1 peptide fragment, which is
up-regulated in newly diagnosed AML patients, may de-
crease and approach to the normal level in their relative
intensities after complete remission. When AML refrac-
tory & relapsed, the relative intensity is elevated again.
Results are contrary to isoform 1 of fibrinogen alpha of
chain precursor peptide fragment and PF4. Kaplan–
Meier analyses of overall survival show that relative in-
tensity of peptides is correlated with patient’s clinical
outcome. We speculate these peptides can be used as po-
tential markers for predicting AML relapse, monitoring
minimal residual disease and assessing clinical outcome.
Methods
Patients’ clinical data and serum samples
This study was approved by the institutional Ethics
Committee of the Hospital. 72 adult AML patients were
randomly selected from those whose diagnosis was con-
firmed by myelocytic cytological diagnosis in the Second
Affiliated Hospital of Xi’an Jiao Tong University during
a given period of time (2009.1–2012.1). The diagnosis
to adult AML was conducted based on the French-
American-British (FAB) classification system. At the
same time, 72 healthy controls were selected from adult
healthy examinees without any diseases. In addition, 37
serum samples were obtained from AML patients with
hematologic CR and 30 serum samples from refrac-
tory & relapsed AML patients. A day 15 bone marrow
puncture were performed. The diagnostic standards of
hematologic CR were: bone marrow blasts < 5%; absence
of blasts with Auer rods; absence of extramedullary
disease; absolute neutrophil count > 1.0 × 109/L, platelet
counts > 100 × 109/L, independence of red cell transfu-
sions. Resistant disease (RD) was defined as failure to
achieve CR or CR with incomplete blood recovery (CRi )
(general practice; phase 2/3 trials), or failure to achieve
CR, CRi, or partial remission(PR) (phase 1 trials); only
includes patients surviving 7 days following completion
of initial treatment, with evidence of persistent leukemia
by blood and/or bone marrow examination. Relapse was
defined as bone marrow blasts > 5%; or reappearance of
blasts in the blood; or development of extramedullary
disease. All patients and healthy examinees signed in-
formed consents.
Clinical characteristics of newly diagnosed AML pa-
tients, patients with AML-CR and AML-RD are shown
in Table 5. The serum samples were collected according
to standard protocol. Fasting blood samples were col-
lected from patients in the morning and allowed to clot
at room temperature for 2 h. Sera were then separated
by centrifugation at 2500 rpm for 10 min and stored
at −80°C until analysis. The length of cryo-preservation
Table 5 Clinical features of patients in different AML groups before chemotherapy
Clinical features AML
Newly diagnosed CR Refractory & relapsed
Sex male 38 19 13
female 34 18 17
Age(year) 46(18–79) 48(18–69) 47(19–77)
WBC(×109/L) 23.5(0.25-143) 11.83(2.96-101.69) 23.58(0.94-123.6)
Hb(g/L) 73(28–128) 111.5(69–135) 69(55–152)
PLT(×109/L) 26(12–287) 74(48–174) 31(9–172)
Subtype M0 0 M0 0 M0 0
M1 6 M1 2 M1 3
M2 8 M2 5 M2 2
M3 6 M3 5 M3 0
M4 24 M4 11 M4 13
M5 28 M5 14 M5 12
M6 0 M6 0 M6 0
M7 0 M7 0 M7 0
Chromosome Abnormality t(15;17) 6 t(15;17) 5 t(8;21) 1
t(8;21) 4 t(8;21); 2 t(3;12) 2
t(3;12) 2 11q23 2 11q23 4
11q23 6 +8 3
+8 4 −7 2
−7 2
Molecular Genetics Abnormality PML-RARa 6 PML-RARa 5 AML-ETO 1
AML-ETO 4 AML-ETO 2 MLL 3
MLL 6 FLT3-ITD 5
FLT3-ITD 6 C-kit Mut 2
C-kit 3 NPM1 Mut 3
NPM1 Mut 3
Sternal tenderness 57/72 25/37 26/30
Lymphadenectasis 39/72 14/37 21/30
Splenohepatomegalia 36/72 16/37 14/30
Curative effect 32/72 37/37 17/30
This table showed clinical features of AML patients in different groups at the time of diagnosis. MLL refers to MLL rearrangement. Mut is the abbreviation of
mutation. Curative effect refers to achieved complete remission after 2 courses of standard chemotherapy.
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[39]. For the reproducibility experiments, serum from
each AML patient and each healthy control used the
same MALDI-TOF-MS instrument to run three within-
run assays and three between-run assays.
Weak cation exchange magnetic beads based serum
peptides purification
Weak cation exchange magnetic beads kit was pur-
chased from Bruker Daltonics Inc. (Billerica, MA · USA).
All purifications were performed in a one-step proce-
dure according to manufacturers’ instructions through a
standard protocol (ClinProtTM, Bruker Daltonics).1) 5 μl serum samples, 10 μl Binding Buffer and
10 μl MB-WCX were mixed by pipetting in a 200 μL
Orcugen sample tube. 2) After 5 minutes standing, the
tube was placed in a magnetic bead separator for 1 min.
Then the supernatant was discarded carefully with a pip-
ette. 3) Subsequently 100 μl Washing Buffer was added,
the tube was moved to and fro in two adjacent holes of
the magnet separator, and then placed in the magnet
separator for 1 min so as to make magnetic beads ad-
here to the wall of the tube. Afterwards, the supernatant
was discarded carefully using a pipette. 4) Washing
process was repeated twice. After binding and washing,
5 μl Elution Buffer was added to the tube to elute the
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tube was placed in the magnet separator for 2 min. After
that, the supernatant was transferred into a 0.5 ml tube
with 5 μl Stabilization Buffer. Binding, Washing, Elution,
and Stabilization Buffer were all provided by Bruker
Daltonics Inc. 5) Matrix preparation: matrix solution with
α-Cyano-4- hydroxycinnamic acid (HCCA) of 0.3 g/l in
ethanol: acetone 2:1 (prepared freshly every day).
Data acquisition by MALDI-TOF mass spectrometry
1) At first, 1 μL eluted sample was spotted onto a
MALDI-TOF AnchorChip (TM) target (600 μm anchor
diameter), and air-dried at room temperature, then 1 μL
matrix (0.3 mg/ml HCCA, 50% ACN, 2% TFA) was
spotted onto MALDI-TOF AnchorChip. 2) Anchorchip
target plate was placed into the Micro flex mass spec-
trometer (Bruker Daltonics). 3) After calibration of in-
strument by cilnplot standard, samples were detected,
scan range was 0.7-l0KD. FlexControl2.2 software was
applied to acquire data and peptide profiling was consti-
tuted by different mass to charge ratio.
Data processing and statistical analysis
Original mass spectrums were normalized by Flex-
analysis 3.0 software, including soomthing and substrate
baseline. Where after, we selected statistical algorithm
built-in Clinprotools2.2 software for statistical analysis
and acquization of differently expressed peptides. ANOVA
test or Wilcoxon rank sum test was used to analyse pep-
tide peak intensity differences in each group. Statistically
significant was defined as p < 0.05. GA, SNN and QC were
applied to establish model to distinguish AML and healthy
control. The patients were categorized into two groups
according to the relative intensities of peptides (≥mean
versus <mean). Overall Survival was estimated by the
Kaplan-Meier method and compared using a log-rank
test. The event was defined as the time from initial diag-
nosis to treatment-related death time.
Identification of peptide biomarkers
We utilized a nano-liquid chromatography–electro spray
ionization–tandem mass spectrometry (nano-LC/ESI–
mass spectrometry/mass spectrometry) system consis-
ting of an Aquity UPLC system (Waters Corporation,
Milford, USA) and a LTQ Obitrap XL mass spectrom-
eter (Thermo Fisher, waltham, MA,USA) equipped with
a nano-ESI source(Michrom Bioresources, Auburn, USA)
to perform peptide sequencing and peptide identification.
The peptide solutions purified by magnetic beads, were
loaded to a C18 trap column (nanoACQUITY) (180 μm×
20 mm× 5 μm (symmetry)). The flow rate was 15 μl/min.
Then the desalted peptides were analyzed by C18 analyti-
cal column (nano ACQUITY) (75 μm× 150 mm× 3.5 μm
(symmetry)) at a flow rate of 400 nl/min for 60 min. Themobile phases A (5% acetonitrile, 0.1% formic acid) and B
(95% acetonitrile, 0.1% formic acid) were used for analy-
tical columns. The gradient elution profile was as follows:
5%B–45%B–80%B–80%B–5%B–5%B in 60 min. The spray
voltage was 1.8 kV. MS scan time was 60 min. Experimen-
tal mode were Data Dependent and Dynamic Exclusion,
scilicet a second cascade of the parent ion within 10
seconds added to the exclusion list for 90 seconds. Mass
scan range was from m/z 400 to 2000. MS scan used
Obitrap, resolution was set at 100000. CID and MS/MS
scan applied LTQ. In MS spectrogram, we selected single
isotope composed of 10 ions with strongest intensity as
parent ion for MS/MS (Single charge being excluded, not
as parent ion). We applied data analysis software Bioworks
Browser 3.3.1 SP1 for Sequest™ retrieving. Retrieval Data-
base was International Protein Index (IPI human v3.45
fasta with 71983 entries). Parent ion error was set at
100 ppm, fragment ions error at 1 Da, digested mode
at non-digested and variable modifications at methio-
nine oxidation.
Determination of serum PF4 by ELISA
We used ELISA to assay serum PF4 content in 40 newly
diagnosed AML patients and 40 healthy controls and
compared the differences between the two groups. De-
tailed procedure was according to manufacturers’ instruc-
tions of ELISA kit (R&D, USA). Furthermore, we analyzed
the correlation of platelet counts and serum PF4 content
in AML patients. Independent sample t-test comparative
analysis was done through the statistical software SPSS
17.0. Correlation analysis used linear regression analysis.
Statistically significant was defined as p < 0.05.
Western blot analysis for validation
Sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) and immunoblotting were performed
essentially as described elsewhere. Briefly, cell pellets
were resuspended on ice in lysis buffer containing
10 mM Tris–HCl (pH 7.4), 5 mM MgCl2, 1% Triton
X-100, 100 mM NaCl, 10 mM NaF, 1 mM Na3VO4 and
a protease inhibitor cocktail. After sonication, cellular
proteins were separated on an SDS-polyacrylamide gel
and transferred to polyvinylidene fluoride membranes
(Roche Diagnostics Corporation, Indianapolis, Indiana
United States), which were probed with the appropriate
primary antibodies. Immunoreactivity was detected with
the relevant horseradish peroxidase-labeled secondary
anti-bodies which, in turn, were visualized on an Image
Reader Tano-5500 (Tano, Shanghai, China) using che-
miluminescence substrate reagent purchased from 7 sea
pharmtech (Shanghai, China) For quantification of the
data, the images were further analyzed on the same in-
strument using 2D Densitometry Image Analyzer IPP
7.0 software (Tano, Shanghai, China).
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Additional file 1: Figure S1. Serum peptide fingerprints of the same
serum through same processing in three-repeated experiments. (A)
Serum peptide fingerprints of the same acute leukemia through same
processing in three-repeated experiments. (B) Serum peptide fingerprints
of the same healthy control through same processing in three-repeated
experiments.
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